 SOUTH SAN FRANCISCO, Calif., April 28, 2021 GLOBE NEWSWIRE -- Nkarta, Inc. Nasdaq: NKTX, a biopharmaceutical company developing engineered natural killer NK cell therapies to treat cancer, today announced that the U.S. Food Drug Administration FDA has cleared an Investigational New Drug IND application to study NKX019 in patients with relapsed or refractory B cell malignancies. 